A prospective, 1-year follow-up study of postural tachycardia syndrome.
Kurt Kimpinski, Juan J Figueroa, Wolfgang Singer, David M Sletten, Valeria Iodice, Paola Sandroni, Philip R Fischer, Tonette L Opfer-Gehrking, Jade A Gehrking, Phillip A Low
Index: Mayo Clin. Proc. 87(8) , 746-52, (2012)
Full Text: HTML
Abstract
To prospectively evaluate patients who met standard criteria for postural tachycardia syndrome (POTS), at baseline and 1-year follow-up, using standard clinical and laboratory methods to assess autonomic function.Fifty-eight patients met the study criteria (orthostatic symptoms and a heart rate increment of ≥ 30 beats/min on head-up tilt) and completed 12 months of follow-up. All patients were enrolled and completed the study from January 16, 2006, through April 15, 2009. Patients underwent standardized autonomic testing, including head-up tilt, clinical assessment, and validated questionnaires designed to determine the severity of autonomic symptoms.Patients were predominantly young females (n=49, 84%), with 20 patients (34%) reporting an antecedent viral infection before onset of symptoms. More than one-third (37%) no longer fulfilled tilt criteria for POTS on follow-up, although heart rate increment on head-up tilt did not differ significantly at 1 year (33.8 ± 15.1 beats/min) compared with baseline (37.8 ± 14.6 beats/min) for the entire cohort. Orthostatic symptoms improved in most patients. Autonomic dysfunction was mild as defined by a Composite Autonomic Severity Score of 3 or less in 55 patients (95%) at baseline and 48 patients (92%) at 1 year.To our knowledge, this is the first prospective study of the clinical outcomes of patients with POTS. Orthostatic symptoms improved in our patients, with more than one-third of patients no longer fulfilling tilt criteria for POTS, although the overall group change in heart rate increment was modest. Our data are in keeping with a relatively favorable prognosis in most patients with POTS.Copyright © 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
Related Compounds
Related Articles:
2015-01-01
[PLoS ONE 10(3) , e0119579, (2015)]
2013-01-01
[BMJ Case Rep. 2013 , doi:10.1136/bcr-2012-007577, (2013)]
2014-09-01
[Neurotoxicology 44 , 80-90, (2014)]
2013-09-01
[Drug Dev. Ind. Pharm. 39(9) , 1364-71, (2013)]
2015-04-01
[Drug Chem. Toxicol. 38 , 126-32, (2015)]